ISL
TEVA icon

Ingalls & Snyder LLC’s Teva Pharmaceuticals TEVA Stock Holding History

Ingalls & Snyder LLC’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$168K – 497
2025
Q2 		$168K Hold
10,000
– – 0.01% 434
2025
Q1 		$154K Buy
+10,000
New +$179K 0.01% 423
2017
Q3 		– Sell
-8,188
Closed -$272K – 377
2017
Q2 		$272K Buy
+8,188
New +$253K 0.01% 305

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Ingalls & Snyder LLC's TEVA Position: Q3 2025 in Review

Ingalls & Snyder LLC sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 10,000 shares — an estimated $168K sold.

Ingalls & Snyder LLC first reported a position in TEVA in Q2 2017 and held it in 3 quarters. The position peaked at $272K in Q2 2017. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Ingalls & Snyder LLC reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 10,000 Teva Pharmaceuticals shares in Q3 2025, an estimated $168K.
  • Ingalls & Snyder LLC first reported a position in Teva Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Ingalls & Snyder LLC's Teva Pharmaceuticals position peaked at $272K in Q2 2017.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2025, filed 7 Nov 2025.